Gefitinib (ZD1839)

Catalog No.S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Cited by 165 Publications

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )
Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )
Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )
Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )
Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )
PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )
Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	M3HhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS2XYZnUUN3ME2wMlA2PCEQvF2=	MoP2NVY2OTZ2N{O=
NIH3T3	MXLGeY5kfGmxbjDBd5NigQ>?	MV:wMlIh\|ryP	NXXHboRzOiCq	NXzFXHdZTE2VTx?=	NWjKcpdSUW6qaXLpeIlwdiCxZjDFS2Yhe3SrbYXsZZRm\CCqdX3hckBmemKEMTDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCxOFQh\|ryP	MVGxOlQ5ODJ6NB?=
COS7	M4\XTmZ2dmO2aX;uJGF{e2G7	NV3OdZliQTZizszN			MnLkTY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>	MlPtNVcyPzh5MkK=
A549	NEf3ZnZEgXSxdH;4bYMhSXO\|YYm=		M4HPflk3KGh?	MmjwSG1UVw>?	MXfJR\|UxRTF\|LkW5JO69VQ>?	MnXBNVg{OTN6MEe=
K562	NHqzZo9EgXSxdH;4bYMhSXO\|YYm=		NIDjSmI6PiCq	NX\UW5dLTE2VTx?=	M1O3VGlEPTB;OT6zOkDPxE1?	MWixPFMyOzhyNx?=
MDA-MB-231	MXXDfZRwfG:6aXOgRZN{[Xl?		NHvjUZQ6PiCq	MkS0SG1UVw>?	MnfETWM2OD1\|Nj62NUDPxE1?	NV\lSGxbOTh\|MUO4NFc>
MOLT4	MX7DfZRwfG:6aXOgRZN{[Xl?		NVzJWGhkQTZiaB?=	M2C2OmROW09?	NF72cWNKSzVyPUG1MlAzKM7:TR?=	NFfz[3MyQDNzM{iwOy=>
MCF7	NH;ub3BEgXSxdH;4bYMhSXO\|YYm=	MoXTOVAh\|ryP	MYi3NkBp		MlfrTWM2OD1zMj6wOUDPxE1?	MmnMNVg4PzF6MUm=
BT474	M{DDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV[3NkBp		M1S3O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	MXuxPVAzQDR{NB?=
HN5	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHHRNFE4OiCq		M4DvZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKge4l1cCCHQ{WwJI9nKDBwMEGg{txO	MnfTNVkxOjh2MkS=
BA/F3	Mnf3R5l1d3SxeHnjJGF{e2G7		NWn1fIR7PzJiaB?=		NH25RZpEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	M1P3NVE6OjN7MkK5
NIH3T3	NFLpNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHLDXWg4OiCq		MoXWS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	NY\pfY92OTl4NkWzO\|c>
MCF7 MX	MkmySpVv[3Srb36gRZN{[Xl?		M2\ZPFMxKG2rbh?=		NV73fYE5UW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4yKM7:TR?=	NXG0UWFSOTl7M{K5OlA>
A431	NX\TeFU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;pNVAh\|ryP	NEXkZYM4OiCq		NH23OGpIUTVyPUCuOVE1KM7:TR?=	M4frd\|E6QTZ7NE[1
A431	MXfLbY5ie2ViQYPzZZk>	M3npSFAvOSEQvF2=	MlnMNUBp		MWrJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	NFLRNGoyQTl4OUS2OS=>
A431	NYHQd29pU2mwYYPlJGF{e2G7	Mmr1NVAxKM7:TR?=	M2POdFExKG2rbh?=		M{DjXXBzd2yxbnfl[EBqdmirYnn0c5J6KGGldHn2bZR6KG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	MnjaNVk6Pjl2NkW=
Sf9	MnjKT4lv[XOnIFHzd4F6		M1zOO\|ExKG2rbh?=	NYrq[oZRTE2VTx?=	M1jjXWlvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	MkmzNlAxPTZ2MkW=
NCI-H1975	NF6wdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TpSFUh\|ryP	NV3JSGE5PzJiaB?=		NFHuV4NKSzVyPUiuNlYh\|ryP	M1[4eFIxOTVzNkew
NCI-H1975	MXTLbY5ie2ViQYPzZZk>	MlnyNVAh\|ryP			NEXvfGdKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	Mni5NlAyPTF4N{C=
NCI-H1975	M33RS2Z2dmO2aX;uJGF{e2G7	NWLHeYRiOTBizszN			NXjWT4xUUW6qaXLpeIlwdiCxZjDFVmJDOiCjdYTvdIhwe3Cqb4L5cIF1cW:w	NXXpflc1OjBzNUG2O\|A>
NCI-H1975	M3nnWGZ2dmO2aX;uJGF{e2G7	NYnycpRCPSEQvF2=	NGPI[pg1QCCq		NYrGW2R4UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2VvMx?=	MXWyNFE2OTZ5MB?=
A375	M3foPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NI\tdZE1QCCq		M4LUSmlEPTB;MkCuOVUh\|ryP	M1jiXFIxOzB2NUO3
SMMC7721	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvzOFghcA>?		MkLHTWM2OD1\|Mz6xNkDPxE1?	M3vYUVIxOzB2NUO3
DU145	NWnFfHdvS3m2b4TvfIlkKEG\|c3H5		NEDX[242KGR?	MWLEUXNQ	Ml;mTWM2OD12Mj6xO{DPxE1?	M3LPOlIxPDZ4NUW1
MIAPaCa2	M2rp[mN6fG:2b4jpZ{BCe3OjeR?=		MWW1JIQ>	NHjqWYdFVVOR	MUnJR\|UxRTVyLk[yJO69VQ>?	MlHsNlA1PjZ3NUW=
PANC1	MWjDfZRwfG:6aXOgRZN{[Xl?		NUXvOYxpPSCm	M3LBWGROW09?	MX;JR\|UxRTRyLkSyJO69VQ>?	NW\sSI16OjB2Nk[1OVU>
PC9	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfxeY5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVITlJvZHXmbYNq\W62IHj1cYFvKFCFOTDj[YxteyC5aYToJGVEPTBib3[gNE4xOTdizszN	NVfBbXE2OjF{MEi4NFI>
PC9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjJc5pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdzd3e2aD3y[ZNqe3SjboSgbJVu[W5iUFO5JINmdGy\|IHX4dJJme3OrbnegSWdHWiCHN{S2Y2E4PTBxVEe5NG0hdXW2YX70JJdqfGhiRVO1NEBw\iB5IN88US=>	MUCyNVIxQDhyMh?=
PC3	M1HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	M373flczKGh?	M2\2WGROW09?	M{HCVWlEPTB;Nz60JO69VQ>?	MnXTNlE{PTN3NE[=
MDA-MB-468	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PsfVExOCEQvF2=	MXO0PEBp	MXXEUXNQ	NFfDZYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fS=>	NYHGUJFxOjF2Mkm2N\|I>
Plasmodium falciparum					MlrTdWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?	NW[3dlNpOjF6MUewOFU>
NCI-H1993	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFv3Toc4OiCq	M2TxXGROW09?	NH7sVnlKSzVyPUCuNUDPxE1?	NHLoWG8zOTlzNkSzNy=>
NCI-H292	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEjCPFY4OiCq	MlPnSG1UVw>?	M3LvWGlEPTB;MD6wNkDPxE1?	MkDqNlE6OTZ2M{O=
A431	MYTLbY5ie2ViQYPzZZk>		NEjLcmgzKGh?	NFjvOZNFVVOR	M4jZVmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh\|ryP	NEL4WYQzOjFyMUGzNi=>
MCF7	M1LTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHsNVAxyqEQvHevcWw>	MnnVOFghcA>?	M{DCdGROW09?	NGG0bpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkBo\W6nIIfpeIghUUN3MDDv[kAyOi5yNTFOwG0>	NUHYeHpqOjJzMUmxN\|A>
BT474	MoTMR5l1d3SxeHnjJGF{e2G7	MVuxNEDPxE1?	Mki1OFghcA>?		NILoNGVEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzz	MoDZNlIyOzh\|MEi=
MCF7	Ml7FR5l1d3SxeHnjJGF{e2G7	NEHJe\|QyOCEQvF2=	MX:0PEBp		NF;pUW9EgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIF3DSlch[2WubIOgc5Zmei2neIDy[ZN{cW6pIFXyZmIzKGOnbHzz	MYCyNlE{QDNyOB?=
HCC827	M3vsWWtqdmG\|ZTDBd5NigQ>?	M17w[VAvOTJ3IN88US=>	NGW4eIMzPCCq	M4Lv[GROW09?	M3zDUmlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	MV[yNlM{QTN2Mh?=
HCC827	NHXQNlVMcW6jc3WgRZN{[Xl?	MmPENE4yOjVizszN	MUeyOEBp	Ml[4SG1UVw>?	M4Wy[GlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	NETpfmgzOjN\|OUO0Ni=>
HCC827	MUDLbY5ie2ViQYPzZZk>	M3XCVVAvOTJ3IN88US=>	MkfnNlQhcA>?	M3GxNWROW09?	M3;VU2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	NYfrTHF[OjJ\|M{mzOFI>
A431	NVT1dVFsU2mwYYPlJGF{e2G7	MUixNFAh\|ryP	NH3neVQ{OCCvaX6=		NF3sWJdKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MlHnNlI3QTh5OEK=
H460	NYLZ[pBIS3m2b4TvfIlkKEG\|c3H5		NYWzdHlVPzJiaB?=		Ml64TWM2OD13LkW5JO69VQ>?	NGDvNnozOjd{N{S0PS=>
HT-29	M3rjVWN6fG:2b4jpZ{BCe3OjeR?=		NGrHU2w4OiCq		MV3JR\|UxRTNwM{[g{txO	MnzxNlI4Ojd2NEm=
SGC7901	NH\a[YZEgXSxdH;4bYMhSXO\|YYm=		NYfndHRnPzJiaB?=		M3;NfWlEPTB;MUCuNlYh\|ryP	M1LYbVIzPzJ5NES5
A498	NYrnO4NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Ls[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO\|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=	NFzFPXozOjhzOEi0PC=>
Calu3	M13WfGN6fG:2b4jpZ{BCe3OjeR?=	M4XqdlExKM7:Zz;tUC=>	M{foc\|czKGh?		MknCTWM2OD1zLk[g{txO	MmnWNlMyOTZzNki=
FADU	MXTDfZRwfG:6aXOgRZN{[Xl?	M{DIOlExKM7:Zz;tUC=>	NEDlXmM4OiCq		M1LqXGlEPTB;MD6wOUDPxE1?	NE[0elQzOzFzNkG2PC=>
HCC827	NXH2fnVyS3m2b4TvfIlkKEG\|c3H5	MUixNEDPxGdxbVy=	M3;rbVczKGh?		MmXaTWM2OD1yLkCwNVUh\|ryP	NVPZcnRPOjNzMU[xOlg>
PC9	NVTEfHFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPQOWd{OTBizsznM41N	MmHRO\|IhcA>?		NX:1XXVNUUN3ME2wMlAyPCEQvF2=	NGfxXmgzOzFzNkG2PC=>
Sf9	NUX2fJN7U2mwYYPlJGF{e2G7		MUKxJIg>	Mn\1SG1UVw>?	M3v1eWlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLYTh[4dm\CCHR1\SJGw5OzSUIH31eIFvfCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODF3IN88US=>	MmjUNlM3OTF4OUG=
16HBE14o-	NUL4cZo{S3m2b4TvfIlkKEG\|c3H5	M1ziZlExKM7:TR?=	MY[3NkBp	NHzwSWZFVVOR	Mm\sR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVZJSkVzNH:tJINmdGy\|IHjhdoJwemmwZzD3bYxlKHS7cHWgSWdHWiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOTJwN{Gg{txO	NFuwfJYzOzZ4OES0NS=>
NCI-H1975	M1HNRmN6fG:2b4jpZ{BCe3OjeR?=	NE[xUW0yOCEQvF2=	NFPhSHk4OiCq	NXv5RWJDTE2VTx?=	NYrjd5RMS3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch\|ryP	M{\JVlI{PjZ6NESx
16HBE	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXGzSZhEPzJiaB?=	NEnnZ\|ZFVVOR	NUfsNmh4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjCxOmhDTSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHR1\SJJdqfGhiSVO1NEBw\iBzLk[wNUDPxE1?	NGLYNGYzOzd7MkOxPC=>
16HBE	M2TFTmZ2dmO2aX;uJGF{e2G7	M3vyTlExOCEQvF2=	M37DNFE2OCCvaX6=	M4PWbWROW09?	M1exdWlv\HWldHnvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCqdX3hckAyPkiERTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZT	MmTCNlM4QTJ\|MUi=
A549	NVznfIhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MofsO\|IhcA>?	NEixNGdFVVOR	MmnDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	M3PNW\|I{Pzl{M{G4
SH-SY5Y	MXLDfZRwfG:6aXOgRZN{[Xl?		MYm3NkBp		M4n5b2lEPTB;MUiuNlEh\|ryP	NULTfGdFOjN6N{G5NFk>
LoVo	MlXnT4lv[XOnIFHzd4F6		M1j3WFIhKGh?	NHLSS2xFVVOR	M2nQOmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwME[yJO69VQ>?	M4CxRVI{QTNyOUm0
PC9	NV3wVWo{U2mwYYPlJGF{e2G7		NXG2TXh[OiCq	NXnWO5ptTE2VTx?=	M3PVbmlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?	NGezV2QzOzl\|MEm5OC=>
HCC827	NID5fFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXq3NkBp		NVj5PVE1UUN3ME2wMlAyOiEQvF2=	NWLKd5NjOjN7N{OxOlg>
A549	MXvLbY5ie2ViQYPzZZk>	NFPwO4EyKM7:TR?=	NG\UcZMyKGh?	NYLZbHRnTE2VTx?=	NFfzd2xKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	M4DrbVI{QTh6M{W0
A549	NYPQbmxzTnWwY4Tpc44hSXO\|YYm=	Mom4NUDPxE1?	MYmxJIg>	MnvCSG1UVw>?	Mn;ZR4VtdHWuYYKgeZB1[Wun	MWSyN\|k5QDN3NB?=
HCC827	NEjCVY5McW6jc3WgRZN{[Xl?	NV:0emFYOC53IN88US=>	NUjyeZViOiCq	M4fUZ2ROW09?	MmPsTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	NGnBRWczOzl7M{OyPC=>
HCC827	MVzGeY5kfGmxbjDBd5NigQ>?	NVHiXoFFOC53IN88US=>	NUjLfldHOiCq	NYTNTod{TE2VTx?=	NFXWeppKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	NHHOSYEzOzl7M{OyPC=>
HCC827	M4TiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmxNEDPxE1?	M2rVcVczKGh?	MnXkSG1UVw>?	NUnFZ3BiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBo\W[rdHnubYIue2Wwc3n0bZZmKGi3bXHuJGhESzh{NzDj[YxteyCqYYLic5JqdmdiRVfGVkBGPzR4IITvJGE4PTBiZHXs[ZRqd25id3n0bEBKSzVyIH;mJFAvODB3OEGg{txO	NFT4bYYzPDB3M{[3OC=>
A431	MVrLbY5ie2ViQYPzZZk>	MUixNFAh\|ryP	MkS0N\|AhdWmw		MofKTY5pcWKrdHnvckBw\iCHR1\SJIlvKHOqZXSgcYVu[nKjbnWgeoV{cWOuZYOge4l1cCCLQ{WwJI9nKDFwMTFOwG0>	M1LBOFI1ODl2NEOy
BCRP-MDCK2	NWnDZ\|ZoTnWwY4Tpc44hSXO\|YYm=	NF7SXVcyNjhizszN	NXPve24{PzJiaB?=	NIDGbFVFVVOR	MmL5TY5kemWjc3Wgc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	MlPONlQyQDR{MUO=
BCRP-MDCK2	M3z5TmZ2dmO2aX;uJGF{e2G7	NWK1dmdEOS56IN88US=>	MlTSO\|IhcA>?	M4fxbWROW09?	NEf6SoFT\WS3Y4Tpc44hd2ZicHzhd41iKG2nbXLyZY5mKGW6cILld5Nqd25ib3[gRmNTWCCneIDy[ZN{cW6pIILldI9zfGW{IHflcoUhT0[S	NVL4cHNGOjRzOESyNVM>
MDCK	M2fUUWN6fG:2b4jpZ{BCe3OjeR?=		NWT4eoQyPzJiaB?=	NFG3VG5FVVOR	NGi5SmxIUTVyPUGuOFUh\|ryP	NVuwWldFOjRzOESyNVM>
MDCK2	MUDGeY5kfGmxbjDBd5NigQ>?	MkizNU45KM7:TR?=	MVi3NkBp	NYjrdJRFTE2VTx?=	NHjLelVKdmirYnn0bY9vKG:oIHj1cYFvKEKFUmCg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KEixZXPod5QhOzN\|NEKgZYNkfW23bHH0bY9vKHerdHigTWM2OCCxZjCzMlE6KM7:TR?=	M2PtUVI1OTh2MkGz
A431	M13vOmN6fG:2b4jpZ{BCe3OjeR?=		NEC2dVk4OiCq	Mnu5SG1UVw>?	MmjtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	NYPhS\|kyOjR2MUGxNlM>
Calu3	NY[5Nm5wS3m2b4TvfIlkKEG\|c3H5		NILSPVY4OiCq	M3nUNWROW09?	NFnTXlNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[Wy3MzDj[YxteyCneIDy[ZN{cW6pIFjFVlIhf2m2aDDJR\|UxKG:oIECuPVkh\|ryP	NXLjZYJjOjR2MUGxNlM>
KB	NGixOlJMcW6jc3WgRZN{[Xl?	M4[zTVExKM7:TR?=	NWLpe3V1OSCq	MoXhSG1UVw>?	MUPJcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6wNlUh\|ryP	MUSyOFQyOTF{Mx?=
BEAS2B	M3fqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTUOVAh\|ryP	NXK2eGcyPzJiaB?=	Mk\OSG1UVw>?	MkjhTWM2OD1zMz65OEDPxE1?	NFLGcGEzPDZyN{W5NS=>
NCI-H1975	M3q3WmZ2dmO2aX;uJGF{e2G7	MY[xNFAh\|ryP	NXn6[3pOOTVyIH3pci=>	MmHQSG1UVw>?	NES3[3BKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	MX2yOFYxPzV7MR?=
Hela	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU[3XY1bOjRiaB?=	MnPjSG1UVw>?	MWrJR\|UxRTJwNkeg{txO	MnzsNlQ4OzF{OEG=
HepG2	M4TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWOyOEBp	MUTEUXNQ	NWeyN2RqUUN3ME22MlQzKM7:TR?=	MnHCNlQ4OzF{OEG=
Sf9	NULKW29IU2mwYYPlJGF{e2G7		M3mxdVExKG2rbh?=	NEHQe\|VFVVOR	Ml\iTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	NEXmcYczPDd\|MUK4NS=>
SW620	NF7wPYtEgXSxdH;4bYMhSXO\|YYm=		MkjoOFghcA>?	NILmNGxFVVOR	NVzKfWN2UUN3ME2yPE4zKM7:TR?=	M33wSVI1QTByNUm0
HCC827	NYD3Rm9pTnWwY4Tpc44hSXO\|YYm=	NGG4XpAxNjVizszN	NEDIfHIzKGh?	M3TM[2ROW09?	NFXTNVdld2W\|IH7veEBqdmirYnn0JIMuVWW2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbh?=	Mne0NlM6QTN\|Mki=
HCC827	Mn\5SpVv[3Srb36gRZN{[Xl?	NIW0fIIxNjVizszN	MX6yJIg>	MmC4SG1UVw>?	NVvv[YM2\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIC0OE81OiCyaH;zdIhwenmuYYTpc44>	NWG3cWJ{OjN7OUOzNlg>
HCC827	MonjR5l1d3SxeHnjJGF{e2G7	NYn1NJlEOC53IN88US=>	Mo\UO\|IhcA>?	M1L2U2ROW09?	M1m4[4hieyCwbzDjfZRwfG:6aXPpeJk>	NHXiPFUzOzl7M{OyPC=>
NCI-H1975	MWXGeY5kfGmxbjDBd5NigQ>?	MmrrNVAh\|ryP	MnLuPEBp	NFjMXGRFVVOR	M3vRVIRw\XNibn;0JIlvcGmkaYTpJGVITlJiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	M4HxV\|I{OTF4MU[4
A431	MXPLbY5ie2ViQYPzZZk>	Ml\KNUDPxE1?	MmewNUBp	M4nI[mROW09?	MkXTbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MljuNlQ6ODB3OUS=
LNCaP	M3HSNmZ2dmO2aX;uJGF{e2G7	Mnj5NVAh\|ryP	NXPUSoF1Omhib4KgOEBp	MXzEUXNQ	NFjXS5dld2W\|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>	Mk\BNVg3Pjd\|MUK=
H1975	MoHRT4lv[XOnIFHzd4F6	M1z3e\|Eh\|ryP	NVrBSmJVOjRiaB?=	NWXsUYZxTE2VTx?=	M1GxXoRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	MVGyOFYxPzV7MR?=
H1975	M1HCV2Z2dmO2aX;uJGF{e2G7	NXrTO2dROSEQvF2=	NYfKeGlHOjRiaB?=	M2TjZWROW09?	NFfSTXpld2W\|IH7veEBqdmirYnn0JGVTUyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1?	Mn;qNlQ3ODd3OUG=
HCC827	MlvlT4lv[XOnIFHzd4F6	NEfP[lQxNjFzIN88US=>	M2KweFEhcA>?	MkDVSG1UVw>?	Mn3MbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XO\|ZYPz[YQh[XNicnXjc5Zmenlib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	MkD5NlQyOjR6OUi=
H1975	M{PKU2tqdmG\|ZTDBd5NigQ>?	MnrXNE4{OyEQvF2=	NUftZVZCOiCq	NGnVTHhFVVOR	NUTtToVN\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	NWjQXZpqOjRzMkS4PVg>
H1975	NV7DSVlyU2mwYYPlJGF{e2G7	M4rqclAvOzNizszN	M2rtRlIhcA>?	NIXJbohFVVOR	M1XPSoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NFnjSXgzPDF{NEi5PC=>
H1975	M3jpcmtqdmG\|ZTDBd5NigQ>?	NInPZmoxNjN\|IN88US=>	NWjySpc{OiCq	MkDLSG1UVw>?	NGjnT4tld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	MWiyOFEzPDh7OB?=
H1975	MU\LbY5ie2ViQYPzZZk>	NFTOZWExNjF{NTFOwG0>	MYKyOEBp	M4DicWROW09?	NFTQWZhld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	MVyyNlM{QTN2Mh?=
H1975	M4jWcGtqdmG\|ZTDBd5NigQ>?	NFnaWGgxNjVizszN	NVnkXY51OjRiaB?=	M1nTRmROW09?	NYDoWpZj\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;u	NYnoVnFzOjJ\|M{mzOFI>
H1975	M17ZcmtqdmG\|ZTDBd5NigQ>?	M3\V[\|AvPSEQvF2=	NFnjPYczPCCq	NHjVO2dFVVOR	NUDqTIZJ\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDBb5QheGixc4Doc5J6dGG2aX;u	NUn4XphtOjJ\|M{mzOFI>
MIAPaCa2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LwXFIvPSEQvF2=	M{XqTFczKGh?	MmjWSG1UVw>?	NGrEVFBp[XNibn:g[5Jwf3SqIHnubIljcXSrb36=	NWjhXZJ6OjB2Nk[1OVU>
MIAPaCa2	MoGwR5l1d3SxeHnjJGF{e2G7	M{npSlEh\|ryP	NWPpVnl2OTBiZB?=	M{TzXmROW09?	NIi2XnJp[XNibn:gZ5l1d3SxeHnjbZR6KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44>	NXi4VI5JOjB2Nk[1OVU>
MIAPaCa2	NV;wNmE3SXCxcITvd4l{KEG\|c3H5	NV\XSWFJOTBizszN	Mkf4NlRpKG:{IES4JIg>	MoDESG1UVw>?	MmrH[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MoLGNlA1PjZ3NUW=
MIAPaCa2	NYTUdI93SXCxcITvd4l{KEG\|c3H5	M{jsSlIxKM7:TR?=	Mof6NlQhcA>?	NX3zVJh2TE2VTx?=	NV;2eWQ5\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	Ml;zNlA1PjZ3NUW=
EoL-1	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTVwMUegcm0>	MmPsV2FPT0WU
NCI-H720	NVLCdpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjMTWM2OD1{Nj65NkBvVQ>?	M4PBXXNCVkeHUh?=
NCI-SNU-5	M{HDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTae3ZKSzVyPUK4MlE6KG6P	MkfQV2FPT0WU
EW-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLQ[\|hLUUN3ME20Ok4xPCCwTR?=	MnHrV2FPT0WU
HCC2218	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HQeGlEPTB;NUCuOVkhdk1?	MXjTRW5ITVJ?
HuO-3N1	M1nuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLEfllMUUN3ME21Ok4xQSCwTR?=	MnHCV2FPT0WU
DB	MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvpN2xFUUN3ME22NE46PiCwTR?=	M{XyTXNCVkeHUh?=
HSC-4	NHrhZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PkWGlEPTB;NkGuOVMhdk1?	NXfYOJVjW0GQR1XS
DOK	M4nxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLIfJVNUUN3ME25N{43OiCwTR?=	MUfTRW5ITVJ?
H9	NV3mNXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF\|Nz6yJI5O	M17nU3NCVkeHUh?=
NCI-H292	M2jGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLjTWM2OD1zNkKuOlYhdk1?	NF\SUppUSU6JRWK=
HSC-2	NVPDcmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPuOWpKSzVyPUG2OU42PyCwTR?=	Mn7lV2FPT0WU
LU-65	NHOyVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWq1cXpEUUN3ME2xOlYvPjFibl2=	NYK1fWNsW0GQR1XS
BV-173	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHHTWM2OD1zOE[uOVUhdk1?	MXHTRW5ITVJ?
LB2241-RCC	NEfnbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfpPGhKSzVyPUG5OE46OyCwTR?=	MVzTRW5ITVJ?
KG-1	NGHB[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJyND6zOEBvVQ>?	M4D0b3NCVkeHUh?=
CHL-1	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLDTWM2OD1{MEiuOVEhdk1?	MoHKV2FPT0WU
KYSE-140	NV:wXW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO3TWM2OD1{MEmuPVYhdk1?	NHfEVIVUSU6JRWK=
DU-145	NVraepJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjaTWM2OD1{MUmuNFQhdk1?	M4fQSXNCVkeHUh?=
EW-13	M{W3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TrSmlEPTB;MkK1MlEhdk1?	NYf3S\|B6W0GQR1XS
KYSE-450	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LKeGlEPTB;MkS3MlkzKG6P	MmPMV2FPT0WU
CAL-72	M1;QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTJ4OD63N{BvVQ>?	MYfTRW5ITVJ?
MEG-01	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TW[mlEPTB;Mke2Mlc3KG6P	NHnncJdUSU6JRWK=
HCE-T	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJ5OT63PUBvVQ>?	Ml\IV2FPT0WU
NCI-SNU-1	M2iwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7GTWM2OD1{OEOuN\|Ihdk1?	NWHsVYQyW0GQR1XS
CAL-27	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXSUndzUUN3ME2yPFkvODhibl2=	M4LlPXNCVkeHUh?=
BALL-1	M17rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPUSYtKSzVyPUK5O{41OiCwTR?=	NH3PUHJUSU6JRWK=
SBC-1	NInUOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jUOWlEPTB;M{C3Mlc6KG6P	M2q2N3NCVkeHUh?=
CAL-54	NFLXbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHPeJdKSzVyPUOxNU4zOyCwTR?=	M2PqU3NCVkeHUh?=
TI-73	NFXnflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrQTWM2OD1\|MUKuO\|Uhdk1?	NHi1SJhUSU6JRWK=
P12-ICHIKAWA	NWHYWnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHnOGtGUUN3ME2zNlgvODZibl2=	M1T0dnNCVkeHUh?=
ACHN	M1GxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTN\|MT60JI5O	MVPTRW5ITVJ?
PC-14	NHfJfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX31bmRwUUN3ME2zN\|MvPDFibl2=	NX2wZXhPW0GQR1XS
HCC1806	NXXremZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPE[W5iUUN3ME2zN\|cvPTFibl2=	MnTpV2FPT0WU
SK-MEL-24	NXvYeXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTN\|Nz64O{BvVQ>?	NEfhRpVUSU6JRWK=
A4-Fuk	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3mycWlEPTB;M{WwMlAzKG6P	NVKwSG1xW0GQR1XS
ECC10	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf0THVKSzVyPUO1Nk46PiCwTR?=	MluyV2FPT0WU
KASUMI-1	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDxbJZzUUN3ME2zOlYvPzNibl2=	M{jpXHNCVkeHUh?=
CAL-33	M3G3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLSTWM2OD1\|N{CuPUBvVQ>?	M4LkbHNCVkeHUh?=
MDA-MB-175-VII	NHvRNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTN5OD64PEBvVQ>?	NFvQZ2xUSU6JRWK=
NUGC-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\We2tYUUN3ME20NFEvQDFibl2=	MXjTRW5ITVJ?
KY821	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHWd2F4UUN3ME20NFgvPTdibl2=	Mn7BV2FPT0WU
CTB-1	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLXUopKSzVyPUSyOE41KG6P	NXHFe3FLW0GQR1XS
DoTc2-4510	NVjXPHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3W5W2lEPTB;NESyMlEzKG6P	M{nxUXNCVkeHUh?=
EFO-27	NELxV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTOTWM2OD12NUSuO\|Qhdk1?	NF;yNI9USU6JRWK=
BPH-1	NWXCV2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3joUWlEPTB;NEmxMlE3KG6P	NF7DXmtUSU6JRWK=
KYSE-270	NHXu[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTR7OD62OUBvVQ>?	M1fZV3NCVkeHUh?=
HO-1-N-1	M3;2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3WS2hEUUN3ME21NFkvOjVibl2=	MnvnV2FPT0WU
SK-MEL-1	NIq4dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rufWlEPTB;NUGwMlk6KG6P	MlvzV2FPT0WU
MOLT-13	NGHZTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j3RmlEPTB;NUG0MlgzKG6P	M4\6enNCVkeHUh?=
TK10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLEOJZuUUN3ME21NVUvOTFibl2=	MmnEV2FPT0WU
HN	NYj5VmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTVzNz6zPEBvVQ>?	MXjTRW5ITVJ?
SCC-15	NEjCNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPySJBKSzVyPUWyOU43QCCwTR?=	MWnTRW5ITVJ?
NCI-H358	M3izU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlr2TWM2OD13MkeuOlYhdk1?	M36yOHNCVkeHUh?=
KYSE-180	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4L2TmlEPTB;NUOwMlYzKG6P	M1;QTXNCVkeHUh?=
NCI-H82	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTV2MD61JI5O	NFHuVoVUSU6JRWK=
NB7	NX3NN5ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTV2Nj6zNkBvVQ>?	NFrNTYZUSU6JRWK=
DSH1	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTV4Nj64PEBvVQ>?	MnrlV2FPT0WU
RS4-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV33dmgzUUN3ME21OlgvPTlibl2=	MXrTRW5ITVJ?
CAN	NH;JPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjCPIFTUUN3ME21PFAvPzZibl2=	MmDiV2FPT0WU
Ca9-22	NIXyNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjwPYFQUUN3ME21PFgvPjRibl2=	M3HyOnNCVkeHUh?=
CAL-39	M4S3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoW1TWM2OD13OU[uN{BvVQ>?	M2foXnNCVkeHUh?=
NCI-H1623	M1LBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTV7OT6zOkBvVQ>?	NXm5XXNrW0GQR1XS
FADU	M3f3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTZyND62PUBvVQ>?	NGfsUWpUSU6JRWK=
NB69	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f2UGlEPTB;NkG0MlM2KG6P	MWfTRW5ITVJ?
Ramos-2G6-4C10	NGHhfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3sTWM2OD14MkGuOFYhdk1?	NXXFd4xLW0GQR1XS
LB1047-RCC	NH\XbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHhbHl[UUN3ME22NlUvOjlibl2=	MmnCV2FPT0WU
MV-4-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\nTWM2OD14MkeuO{BvVQ>?	M{TLTXNCVkeHUh?=
DBTRG-05MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrGeoUzUUN3ME22N\|IvOjhibl2=	NVjjN5FEW0GQR1XS
ME-180	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPIWXJKSzVyPU[zNk46KG6P	MVfTRW5ITVJ?
NBsusSR	M4LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHSTWM2OD14NE[uOVIhdk1?	MmPPV2FPT0WU
COR-L105	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3JXHJyUUN3ME22OlIvPTNibl2=	NGPzSVRUSU6JRWK=
ETK-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\WTmlEPTB;Nk[yMlU6KG6P	MnfQV2FPT0WU
L-363	NILRNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXwNHpKSzVyPU[3NU46PCCwTR?=	M{DHUHNCVkeHUh?=
LU-134-A	NETLPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPBNFVKSzVyPUexPU4xQSCwTR?=	M4Lqe3NCVkeHUh?=
NCI-H1770	M1e1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXzeXJ[UUN3ME23NlIvPCCwTR?=	NF7tVJFUSU6JRWK=
HAL-01	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfOTWM2OD15M{SuO\|Ehdk1?	NIG3fVlUSU6JRWK=
COLO-684	M3Lkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknMTWM2OD15NUOuNFEhdk1?	MUjTRW5ITVJ?
TE-6	NFLObJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjJcpNKSzVyPUe2OE4{OSCwTR?=	M4PBXHNCVkeHUh?=
A431	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\R[HdKSzVyPUe4NE4xPCCwTR?=	NHPYVXpUSU6JRWK=
LU-135	NH;z[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\BNWlEPTB;N{izMlA{KG6P	NX3N[nlJW0GQR1XS
EC-GI-10	M4fTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHwOHNKSzVyPUe4PE42OiCwTR?=	M4jBbnNCVkeHUh?=
TE-12	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3q3O2lEPTB;OEKxMlEyKG6P	NIXWfpVUSU6JRWK=
LoVo	NYrFbHI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HHbmlEPTB;OEW5MlA3KG6P	NXrERnU1W0GQR1XS
23132-87	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\6RWlEPTB;OE[0MlI5KG6P	MWPTRW5ITVJ?
AU565	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLNbZd3UUN3ME24OlkvPiCwTR?=	NXXaU5FyW0GQR1XS
DEL	M37sRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLWTFdYUUN3ME24O\|cvPjVibl2=	MYrTRW5ITVJ?
COR-L88	M37LeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nZTmlEPTB;OEiyMlI3KG6P	NEXOWW5USU6JRWK=
NCI-H2126	NH;Oc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLyTWM2OD16OEKuPFMhdk1?	NFL0XoRUSU6JRWK=
CAPAN-1	NHi1U3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTK[5Q4UUN3ME24PFMvOjlibl2=	NWDNPYFkW0GQR1XS
BT-474	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33iWGlEPTB;OUO4MlE1KG6P	NYrneFNyW0GQR1XS
BHY	NXe3T2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPaV4d2UUN3ME25O\|UvPDhibl2=	MYrTRW5ITVJ?
HT-3	NHTCeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPCTWM2OD17OEKuOFEhdk1?	MWjTRW5ITVJ?
SK-NEP-1	M1zwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXlT\|VDUUN3ME25PFkvPDRibl2=	MkDIV2FPT0WU
MS-1	M1G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\PNVJKSzVyPUm5OE43QSCwTR?=	Ml\yV2FPT0WU
DOHH-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDFU3pjUUN3ME2xMlAxODJzIN88US=>	NYDvZm1LW0GQR1XS
NCI-H1304	NH7KRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvTcXFKSzVyPUGuNFE3PDNizszN	NVXUSGx{W0GQR1XS
EM-2	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS3SGlKSzVyPUGuNFMxOTZizszN	MUfTRW5ITVJ?
MHH-PREB-1	NITjOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4f3dGlEPTB;MT6wPFQ2OSEQvF2=	MnfQV2FPT0WU
KU-19-19	M{W4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHtS29YUUN3ME2xMlA5PTRzIN88US=>	Mn7mV2FPT0WU
NCI-H1648	NEXGe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rWZ2lEPTB;MT6xNFYyPiEQvF2=	NFvtSmtUSU6JRWK=
MKN1	NW\DWo5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFwMkG5PFch\|ryP	NF;RbWxUSU6JRWK=
SNU-449	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfwTWM2OD1zLkKyNlA5KM7:TR?=	NWHJXlV7W0GQR1XS
OAW-42	M{m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTFwMke4NlUh\|ryP	NUf5blc3W0GQR1XS
769-P	NXTkZ3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTaVlB5UUN3ME2xMlI4QTF6IN88US=>	NH7FflJUSU6JRWK=
SW1088	NYO1Zlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEOyXI9KSzVyPUGuNlk3ODdizszN	NXn5VpdIW0GQR1XS
GCIY	M3G4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjMeYxKSzVyPUGuN\|AyOzJizszN	M2ixUHNCVkeHUh?=
CTV-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPldllKSzVyPUGuN\|A5KM7:TR?=	NHzIN2VUSU6JRWK=
NCI-H1092	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwM{C4OUDPxE1?	MnT6V2FPT0WU
NKM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLUTGY6UUN3ME2xMlMzPTl5IN88US=>	NH7vdFBUSU6JRWK=
NCI-H1650	MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;OTWM2OD1zLkOzOFgzKM7:TR?=	MoG5V2FPT0WU
SW954	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnUOJpKSzVyPUGuN\|QxPDhizszN	NGnkUHNUSU6JRWK=
SW48	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwM{[2NVgh\|ryP	NIXwT4FUSU6JRWK=
SK-N-DZ	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHNV2pKSzVyPUGuN\|Y6PDdizszN	NIDYbopUSU6JRWK=
KMOE-2	NUDHfIdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vvUmlEPTB;MT6zPVgyPSEQvF2=	M3X0WnNCVkeHUh?=
NB5	NGf4TJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1GzW2lEPTB;MT60NFg6PCEQvF2=	Mn;aV2FPT0WU
CCRF-CEM	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP0TWM2OD1zLkSxNVEh\|ryP	NFrTUZdUSU6JRWK=
RH-1	M4TuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLqTWM2OD1zLkSxNVM3KM7:TR?=	MULTRW5ITVJ?
NCI-H526	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrZSG1KSzVyPUGuOFM5OjZizszN	MXHTRW5ITVJ?
697	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfjTWM2OD1zLkS0NVA1KM7:TR?=	MkXpV2FPT0WU
J82	NI\RS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPMTWM2OD1zLkS1O\|Y3KM7:TR?=	M2fzW3NCVkeHUh?=
BE-13	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXU[GU1UUN3ME2xMlUxPjdzIN88US=>	M4G5cnNCVkeHUh?=
SAS	NH7tSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzWTWM2OD1zLkWxOlIzKM7:TR?=	MoThV2FPT0WU
SCC-25	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTFwNUKzNlIh\|ryP	NYq2ZphLW0GQR1XS
LAMA-84	NFHpe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfFfW16UUN3ME2xMlU{QDF3IN88US=>	M{HJcHNCVkeHUh?=
HSC-3	NHvkb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;jZlliUUN3ME2xMlU1OzhizszN	NHuxSWNUSU6JRWK=
BT-549	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjpNJdKSzVyPUGuOVg4PDdizszN	NGG2doFUSU6JRWK=
ML-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnHbpZLUUN3ME2xMlY1ODJ7IN88US=>	NVLRZopSW0GQR1XS
BB30-HNC	M3TjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jVcWlEPTB;MT62PFk4OiEQvF2=	Mm\WV2FPT0WU
PANC-03-27	NIHpbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwN{CxN\|kh\|ryP	MVXTRW5ITVJ?
COLO-678	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXqcFNKSzVyPUGuO\|M1PDRizszN	MmrGV2FPT0WU
NCI-H1666	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPVUXpKSzVyPUGuO\|Q4ODRizszN	NH3VRYNUSU6JRWK=
NCI-H209	M2P5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFwN{eyOlkh\|ryP	MWrTRW5ITVJ?
EPLC-272H	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjiZWRKSzVyPUGuPFU2PDlizszN	M4PT[3NCVkeHUh?=
OMC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwOUm4PFgh\|ryP	NFPiclZUSU6JRWK=
HCC70	M4PJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfjfIJKSzVyPUKuNFA5OTVizszN	MUDTRW5ITVJ?
CAL-12T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fMVmlEPTB;Mj6wNVg3OSEQvF2=	NWP2cnBQW0GQR1XS
TGBC24TKB	M4TVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwMEK5OlEh\|ryP	MUPTRW5ITVJ?
EKVX	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XxZmlEPTB;Mj6wOFk{QSEQvF2=	NHzm[GxUSU6JRWK=
SW1116	NWqxbIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7ndJpKSzVyPUKuNFYxODlizszN	MmeyV2FPT0WU
NCI-H2009	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLsbWZnUUN3ME2yMlA3OjF2IN88US=>	NFPPOlhUSU6JRWK=
RPMI-8866	NVL2ZVlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJwMEi0PFEh\|ryP	NETjbHBUSU6JRWK=
KARPAS-45	NFvHRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJwMUK0O\|kh\|ryP	M1WyW3NCVkeHUh?=
RXF393	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwMUOwN\|Yh\|ryP	NXXXZpVtW0GQR1XS
786-0	Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXveG1KSzVyPUKuNVg1ODZizszN	MXPTRW5ITVJ?
SCC-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJwMkG3O\|Yh\|ryP	NHPvXoZUSU6JRWK=
BT-20	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDYUWRSUUN3ME2yMlI3PzR2IN88US=>	MWfTRW5ITVJ?
A498	M{XmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LQSGlEPTB;Mj6yPVQyPSEQvF2=	MmPDV2FPT0WU
IGROV-1	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYCzT5RFUUN3ME2yMlMyOjN5IN88US=>	Mlj2V2FPT0WU
JVM-3	NXPIXmpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLocI5zUUN3ME2yMlM1PjR\|IN88US=>	M1PHXXNCVkeHUh?=
NCI-H2170	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X2WmlEPTB;Mj6zOFc5OyEQvF2=	M1OwcHNCVkeHUh?=
EW-18	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjuVlJEUUN3ME2yMlM2PDdzIN88US=>	NIP4Z2tUSU6JRWK=
KU812	NV3NW5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjLTWM2OD1{LkO2O\|c6KM7:TR?=	NICzfJVUSU6JRWK=
NY	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3jR3VKSzVyPUKuN\|czPyEQvF2=	NWWxc4pJW0GQR1XS
HTC-C3	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF30WmNKSzVyPUKuOFIzPjdizszN	Mm[0V2FPT0WU
CFPAC-1	NEjZb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnMTWM2OD1{LkSzPFY1KM7:TR?=	MWDTRW5ITVJ?
HH	M4fqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTJwNEm4OVQh\|ryP	MYjTRW5ITVJ?
MKN7	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;U[pdKSzVyPUKuOlI4PDhizszN	M2TWTHNCVkeHUh?=
TE-8	NVThW\|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwNkO2OVMh\|ryP	MmHxV2FPT0WU
MC-IXC	NV7sWXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3kcpN[UUN3ME2yMlY1PDV\|IN88US=>	M1fDfHNCVkeHUh?=
DMS-79	M1zz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJwNkmyPFQh\|ryP	MXnTRW5ITVJ?
Detroit562	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXWd5RKSzVyPUKuOlk5PDVizszN	M4f4TnNCVkeHUh?=
HuP-T4	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3PTWM2OD1{LkeyPFE5KM7:TR?=	NW\Mb405W0GQR1XS
QIMR-WIL	M3TjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHzZ3lKSzVyPUKuO\|U6PTJizszN	MVjTRW5ITVJ?
BB65-RCC	NEOzXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJwOEC3NVMh\|ryP	NGKxbnBUSU6JRWK=
PC-3	M4X6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELzVoNKSzVyPUKuPFM{OTdizszN	NXfUUYZ7W0GQR1XS
OVCAR-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHqXYFKSzVyPUKuPFU2QTRizszN	NFLnb25USU6JRWK=
KYSE-510	M3vUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTkSJRqUUN3ME2yMlg3Pzh4IN88US=>	MnTGV2FPT0WU
HC-1	M{XicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHVWY5KSzVyPUKuPVQxOTJizszN	NE\XVXhUSU6JRWK=
NCI-H1693	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nyN2lEPTB;Mj65OVg6PyEQvF2=	NFz2VG5USU6JRWK=
DU-4475	NF\t[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF2zbGZKSzVyPUKuPVkxPTJizszN	MlHDV2FPT0WU
COLO-680N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTaTWM2OD1\|LkCwOFk2KM7:TR?=	MWjTRW5ITVJ?
MN-60	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnvWmtKSzVyPUOuNFQ6PzRizszN	NU\EZ2U6W0GQR1XS
BCPAP	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXrTWM2OD1\|LkC4Nlk2KM7:TR?=	M1\sXnNCVkeHUh?=
647-V	M2G3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTNwMU[yNkDPxE1?	NEewbXVUSU6JRWK=
HT-1376	MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrSTWM2OD1\|LkKwOVA3KM7:TR?=	MXrTRW5ITVJ?
NCI-H1793	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTNwMkGwPVgh\|ryP	M1K1SnNCVkeHUh?=
SW1463	M2THdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTBZ5hKSzVyPUOuNlYyQTJizszN	M13E[3NCVkeHUh?=
NCI-H727	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XXVWlEPTB;Mz6zPFU5PCEQvF2=	NFjjW3pUSU6JRWK=
LB771-HNC	NHi1VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nvWGlEPTB;Mz6zPVEzPiEQvF2=	MnTPV2FPT0WU
D-542MG	NHqy[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWS0WIdVUUN3ME2zMlQ1OjJ{IN88US=>	NGDWSXRUSU6JRWK=
NTERA-S-cl-D1	NFj5RmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrRZYhKSzVyPUOuOFQ6PTdizszN	M2n0bHNCVkeHUh?=
C8166	M13CUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYW3SZpOUUN3ME2zMlQ3PTJzIN88US=>	MWfTRW5ITVJ?
639-V	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTNwNUe3PVIh\|ryP	NITJSmtUSU6JRWK=
TE-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3uwfmlEPTB;Mz61PVE3QSEQvF2=	M2L2[nNCVkeHUh?=
OAW-28	NU[4VpN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnHfGJKSzVyPUOuOVk1OjZizszN	NUi5[Ih{W0GQR1XS
SK-LU-1	NVHmUHlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37vW2lEPTB;Mz62NFY1PSEQvF2=	MYnTRW5ITVJ?
CaR-1	NGfyeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXNRWNKSzVyPUOuOlExPDhizszN	Mmf2V2FPT0WU
A2780	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTNwNkSwPFkh\|ryP	NFfYOWVUSU6JRWK=
C2BBe1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTNwNkS0NFch\|ryP	M4TuNHNCVkeHUh?=
SK-MES-1	M3f2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXr5V3F6UUN3ME2zMlY1PjF2IN88US=>	NETOOG1USU6JRWK=
PANC-10-05	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTNwN{KwO\|Ih\|ryP	Ml\BV2FPT0WU
J-RT3-T3-5	M3XxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnMWnZoUUN3ME2zMlc2PDB4IN88US=>	MYPTRW5ITVJ?
ES4	NIHE[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLOT\|VuUUN3ME2zMlgzOjh4IN88US=>	NUDjeXljW0GQR1XS
NCI-H28	NFLIdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTNwOEK5OlEh\|ryP	NHrwb3lUSU6JRWK=
NCI-H1155	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfkTXZOUUN3ME2zMlg1OTV7IN88US=>	NG[5TG9USU6JRWK=
KURAMOCHI	NFqz[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLwU4xoUUN3ME2zMlg3ODV4IN88US=>	NIPwNW9USU6JRWK=
NCI-H69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;JTWM2OD1\|LkmwNVc5KM7:TR?=	MkTuV2FPT0WU
IST-MES1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTNwOUSwNlkh\|ryP	M{n2OXNCVkeHUh?=
NH-12	NHrkZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlroTWM2OD1\|Lkm0NVg4KM7:TR?=	M{\j[3NCVkeHUh?=
JVM-2	M1jCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNwOUS3OVIh\|ryP	MYjTRW5ITVJ?
EW-16	NUL5SWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnZTWM2OD1\|Lkm1OVc4KM7:TR?=	MUPTRW5ITVJ?
NCI-H441	NWPR[oJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPlNZFSUUN3ME2zMlk4ODF2IN88US=>	MnLHV2FPT0WU
RCC10RGB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nDS2lEPTB;ND6wNVI1PiEQvF2=	M3fpcHNCVkeHUh?=
TCCSUP	M2O2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zMTWlEPTB;ND6xNVA2KM7:TR?=	Mmq2V2FPT0WU
HL-60	NVrnUIl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrVUpVKSzVyPUSuNVIzPDFizszN	NVTXSpRRW0GQR1XS
EW-11	M2jNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfOT5c1UUN3ME20MlE{OjZzIN88US=>	NGHHUXRUSU6JRWK=
KARPAS-299	NXfMdnlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXJV3ZSUUN3ME20MlMyODF\|IN88US=>	NVnkfpZnW0GQR1XS
SNU-C2B	NXjjOXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;ITWM2OD12LkO0Olg3KM7:TR?=	MlHkV2FPT0WU
LU-139	NXfVe2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITaXFVKSzVyPUSuN\|czPDdizszN	M2PTc3NCVkeHUh?=
HCC1937	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkWxTWM2OD12LkO3PVk{KM7:TR?=	NUPkfYV1W0GQR1XS
GR-ST	M2DPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTRwNEOxPEDPxE1?	MYrTRW5ITVJ?
SK-OV-3	NFr3Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTRwNE[wOFIh\|ryP	M3T3[nNCVkeHUh?=
A172	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL6eXJUUUN3ME20MlU2PTJzIN88US=>	M3z5PXNCVkeHUh?=
NB10	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTRwNUm3PFEh\|ryP	M{HjR3NCVkeHUh?=
P30-OHK	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rBfWlEPTB;ND64NVkzQSEQvF2=	NGnrbXdUSU6JRWK=
KYSE-520	M4ftNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH4blN4UUN3ME20Mlg5ODF6IN88US=>	M2rMW3NCVkeHUh?=
KNS-62	M{fYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHkUWZKSzVyPUSuPVA5ODdizszN	MkTtV2FPT0WU
ES1	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTRwOU[wN\|Uh\|ryP	MYTTRW5ITVJ?
KOSC-2	NUTYe5M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnxNolKSzVyPUSuPVk6PTlizszN	MUHTRW5ITVJ?
TE-9	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HhZmlEPTB;NT6wNVUzPSEQvF2=	MXfTRW5ITVJ?
NCI-H1838	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwMEKwO\|Yh\|ryP	MVnTRW5ITVJ?
KP-N-YN	M2PEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;I[VNKSzVyPUWuNVI2QTFizszN	MV;TRW5ITVJ?
ALL-PO	NE\v[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj0TWM2OD13LkKyOVg4KM7:TR?=	M3nacnNCVkeHUh?=
NOMO-1	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTnTWM2OD13LkKzNVc3KM7:TR?=	MkOwV2FPT0WU
CGTH-W-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTVwM{i1PFQh\|ryP	NWHvVoc4W0GQR1XS
ATN-1	M3HveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTVwNEGxPFQh\|ryP	NGnhcGhUSU6JRWK=
AGS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWG5SIhrUUN3ME21MlQ6PjF6IN88US=>	MnjuV2FPT0WU
SW13	M4fYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXmTWM2OD13LkWzNlY2KM7:TR?=	M1i5T3NCVkeHUh?=
SW1990	NIHSXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTQXo1zUUN3ME21MlYzOjh3IN88US=>	NX;jU2xNW0GQR1XS
BFTC-905	M17IfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfP[ZZvUUN3ME21MlY2QDd6IN88US=>	NG\CN3VUSU6JRWK=
RMG-I	M{P6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\XTWM2OD13Lk[1PVQzKM7:TR?=	NGO2c25USU6JRWK=
HD-MY-Z	NHG4PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTVwNki1PFEh\|ryP	M3fwVHNCVkeHUh?=
HCC1187	NF;5dHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\4OGlEPTB;NT63NVA{OiEQvF2=	MmfhV2FPT0WU
HCC2998	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fEb2lEPTB;NT63NVg4PyEQvF2=	MmW2V2FPT0WU
RT-112	NU\qVYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXQTXNuUUN3ME21MlkxOjR3IN88US=>	M1raSHNCVkeHUh?=
CAKI-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3n1TWlEPTB;Nj6wNFk5PSEQvF2=	NVzwSIZiW0GQR1XS
HDLM-2	M4DJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2roXGlEPTB;Nj6wNVQ5QSEQvF2=	NI\DepJUSU6JRWK=
TE-10	NUjlPI52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXLUHJKSzVyPU[uNFQ5OzNizszN	MkW1V2FPT0WU
KE-37	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjoR2FnUUN3ME22MlA4OjV6IN88US=>	MorzV2FPT0WU
RCM-1	NVPLfpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PMOWlEPTB;Nj6wO\|cyQSEQvF2=	NHLIZYZUSU6JRWK=
Mewo	M3j6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVK3Z3pDUUN3ME22MlEyPDh5IN88US=>	MlniV2FPT0WU
L-428	M1n4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvG[IxKSzVyPU[uNVgxOzdizszN	Mnv2V2FPT0WU
8-MG-BA	NHrabopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTZwMUmzO\|kh\|ryP	MXHTRW5ITVJ?
SK-MEL-28	MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi3XZNKSzVyPU[uNlA6PjdizszN	MV7TRW5ITVJ?
VA-ES-BJ	NUDmZnhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z3WGlEPTB;Nj6zNFQ3OiEQvF2=	NY\yV5pWW0GQR1XS
CAL-120	NIPkW\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkiwTWM2OD14LkS1NVYzKM7:TR?=	NVPkXIx7W0GQR1XS
GAMG	M3fzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\HTWM2OD14LkWwOlIh\|ryP	MYHTRW5ITVJ?
MSTO-221H	M3LMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TTeGlEPTB;Nj61NVE4KM7:TR?=	MWXTRW5ITVJ?
GCT	NFfYXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmG1TWM2OD14LkWzN\|g4KM7:TR?=	NVzaXJoxW0GQR1XS
SH-4	NFrCenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTZwNUi4OFQh\|ryP	M4DOTXNCVkeHUh?=
Calu-3	M1T5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTZwNkW1Olgh\|ryP	NHr0UZRUSU6JRWK=
SK-HEP-1	M{XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEf6O2JKSzVyPU[uO\|E4PTNizszN	MYrTRW5ITVJ?
PFSK-1	MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPLTWM2OD14LkezOFc5KM7:TR?=	MUnTRW5ITVJ?
NB12	NFPE[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTZwN{i0NFQh\|ryP	MnuwV2FPT0WU
A388	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\hTWM2OD14Lki5OVIh\|ryP	NUi4bZpLW0GQR1XS
KLE	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDSWmtKSzVyPU[uPVY2OTZizszN	NH\OOHNUSU6JRWK=
TE-11	NW\6Xol5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nnUWlEPTB;Nz6wOFk3PyEQvF2=	M4Tk[nNCVkeHUh?=
NCI-H2405	NG\a[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jvR2lEPTB;Nz6wPFM6OyEQvF2=	MV7TRW5ITVJ?
OVCAR-4	NF7YTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\udotKSzVyPUeuNVU{PSEQvF2=	MULTRW5ITVJ?
KP-N-YS	NEjNWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\WTW5KUUN3ME23MlE5OTRizszN	MVHTRW5ITVJ?
NOS-1	NFvvO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoewTWM2OD15LkK1PFI5KM7:TR?=	NUL6fI1lW0GQR1XS
DMS-114	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTdwMkm2N\|Eh\|ryP	Ml3KV2FPT0WU
NCI-H2030	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXUTWM2OD15LkOzOlk5KM7:TR?=	MkfsV2FPT0WU
HEL	M4\wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXaTWM2OD15LkO3OVIyKM7:TR?=	NWe4NFJYW0GQR1XS
CAL-62	NF\Oe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjXT5hrUUN3ME23MlM6QDZ4IN88US=>	NEP1SYNUSU6JRWK=
COLO-668	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrITWM2OD15LkSzPVY4KM7:TR?=	NVXyVmtwW0GQR1XS
SKG-IIIa	NHrGc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPwZnR7UUN3ME23MlQ2OzhzIN88US=>	NVLQ[mtZW0GQR1XS
HCC1419	NXfUeGd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLRTWM2OD15LkS2PFM{KM7:TR?=	NYH5bZQ2W0GQR1XS
OS-RC-2	M3fkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrqSGFnUUN3ME23MlQ6QDl2IN88US=>	MmrMV2FPT0WU
COLO-829	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTdwNk[0OlMh\|ryP	M37vc3NCVkeHUh?=
NB13	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD2TWM2OD15LkiyOlY4KM7:TR?=	NIL1PG1USU6JRWK=
DK-MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjmVoNrUUN3ME23Mlg{OjBzIN88US=>	Mn\5V2FPT0WU
SHP-77	NX3aeI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT2fZpKSzVyPUeuPFY3PTNizszN	MVHTRW5ITVJ?
NCI-H661	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTlbG9KSzVyPUiuNFU5PjdizszN	MYHTRW5ITVJ?
AM-38	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O0bmlEPTB;OD6xOlI5KM7:TR?=	NWDqepM{W0GQR1XS
VM-CUB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4G3WWlEPTB;OD6xO\|AzQSEQvF2=	MYrTRW5ITVJ?
KYSE-70	NHP0NnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFexV4tKSzVyPUiuNVk4PjFizszN	M3\ZcXNCVkeHUh?=
5637	NXi2eIs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHEeWZxUUN3ME24MlMyODV3IN88US=>	M2q3SnNCVkeHUh?=
TGBC11TKB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLjTWM2OD16LkS2NVY1KM7:TR?=	NIHTZ4xUSU6JRWK=
EGI-1	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRThwNkCwPFgh\|ryP	MVzTRW5ITVJ?
D-392MG	M4\WdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRThwNk[yNVQh\|ryP	NELsW\|JUSU6JRWK=
A673	NUDheXYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3CdnZKSzVyPUiuOlc3OTFizszN	NIW4bolUSU6JRWK=
COLO-792	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nWWWlEPTB;OD63OFk1PiEQvF2=	MWrTRW5ITVJ?
NCI-H1792	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLkTWM2OD16Lki4PVA{KM7:TR?=	NX64WplPW0GQR1XS
LS-1034	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjZRZNRUUN3ME24Mlk1PjV{IN88US=>	NX7OVZpMW0GQR1XS
D-566MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTQTWM2OD17LkCxPFEh\|ryP	M1zNfHNCVkeHUh?=
NCI-H226	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrLTWM2OD17LkC5JO69VQ>?	NXficG1NW0GQR1XS
ChaGo-K-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDQS5A5UUN3ME25MlExPTd7IN88US=>	MYTTRW5ITVJ?
NCI-H2228	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nOeWlEPTB;OT6xNVA5OSEQvF2=	MoiyV2FPT0WU
RPMI-8226	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfRfog4UUN3ME25MlEyOzB2IN88US=>	MV7TRW5ITVJ?
BFTC-909	NF;K[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HmNGlEPTB;OT6xPFI6PyEQvF2=	MVfTRW5ITVJ?
HPAF-II	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHjRlJKSzVyPUmuNlI2OThizszN	NFnDd3dUSU6JRWK=
Capan-2	NIe0cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXeyclN2UUN3ME25MlQxOTB7IN88US=>	NFy3VYNUSU6JRWK=
IA-LM	NVL5eWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LPZWlEPTB;OT60NVk3PiEQvF2=	NILsbHhUSU6JRWK=
KP-4	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3qTWM2OD17LkS4PFM5KM7:TR?=	MmT6V2FPT0WU
A101D	NHjGXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvG[4JmUUN3ME25MlUyPzF7IN88US=>	M2nXbXNCVkeHUh?=
EFO-21	NITUbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLndJhKSzVyPUmuOVg4OzVizszN	Mn3BV2FPT0WU
C32	NWHJ[mFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTDTWM2OD17Lk[zN\|Qh\|ryP	Mo[zV2FPT0WU
SW837	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPZVIlKSzVyPUmuPFQ5OiEQvF2=	M1W4S3NCVkeHUh?=
OCI-AML2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL3NJdKSzVyPUmuPFY6PiEQvF2=	NIXKWoJUSU6JRWK=
NCI-H1355	NIPiOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmKyTWM2OD17Lkm0NFg5KM7:TR?=	M{DKNHNCVkeHUh?=
NCI-H2342	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFyLkCxOVUh\|ryP	MoLwV2FPT0WU
A204	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrITWM2OD1zMD6wOFY3KM7:TR?=	MUXTRW5ITVJ?
CAL-51	NEnibWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFyLkC4O\|ch\|ryP	MoOzV2FPT0WU
HCE-4	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\iTWM2OD1zMD6xNVIzKM7:TR?=	MVfTRW5ITVJ?
NCI-H810	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFyLkG1PVch\|ryP	NUXZOmFyW0GQR1XS
DJM-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD6PHFKSzVyPUGwMlE4OzJizszN	NEnYfZFUSU6JRWK=
SK-UT-1	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3S1PWlEPTB;MUCuNlU4PCEQvF2=	MoGzV2FPT0WU
U031	M4TGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkW3TWM2OD1zMD6yOlg3KM7:TR?=	NIL6e2dUSU6JRWK=
YH-13	NWHaPYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XTWmlEPTB;MUCuN\|A2PyEQvF2=	NXjkbJF5W0GQR1XS
K5	M2LuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;PZpd[UUN3ME2xNE4{Ozl3IN88US=>	NHvKZXFUSU6JRWK=
HEC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M36zOGlEPTB;MUCuOFA5OSEQvF2=	Mmn2V2FPT0WU
A2058	M3jyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\rRVJKSzVyPUGwMlU1QTFizszN	NV\HOJlqW0GQR1XS
SW962	NYrP[oo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFyLk[yNFQh\|ryP	M1PpOnNCVkeHUh?=
VMRC-RCZ	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfMPYRKSzVyPUGwMlY4PDlizszN	NUPpenFuW0GQR1XS
D-336MG	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml33TWM2OD1zMD63NFA2KM7:TR?=	MmnwV2FPT0WU
LXF-289	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PIPGlEPTB;MUCuO\|k3PyEQvF2=	NWrXT3VlW0GQR1XS
SW900	M2rPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPwTWM2OD1zMD64NlI5KM7:TR?=	M2GzT3NCVkeHUh?=
K-562	NFm4e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjlWFdKSzVyPUGwMlg{QTVizszN	MYrTRW5ITVJ?
HCC38	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnq1TWM2OD1zMD65O\|E3KM7:TR?=	M2HBfXNCVkeHUh?=
SF-295	M{LiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFyLkm5NFIh\|ryP	Mmj0V2FPT0WU
LB831-BLC	NUTNe3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTFzLkK1OVYh\|ryP	MknIV2FPT0WU
FTC-133	NX\FUmVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXK1[llNUUN3ME2xNU4{ODhzIN88US=>	MlPvV2FPT0WU
HCC1954	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnncGtzUUN3ME2xNU41OzZizszN	M{PEVHNCVkeHUh?=
GOTO	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFzLkWyNFYh\|ryP	MmXYV2FPT0WU
LS-411N	NVXwPWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[4[GlEPTB;MUGuOlExOSEQvF2=	NGnpbo5USU6JRWK=
RPMI-7951	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTFzLk[zOFgh\|ryP	MonuV2FPT0WU
NCI-H1299	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTFzLk[2OFch\|ryP	NHX5OIlUSU6JRWK=
MLMA	NWn3RmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFzLk[5PVch\|ryP	MmnBV2FPT0WU
MMAC-SF	NFvvNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFzLkeyOVIh\|ryP	MVrTRW5ITVJ?
UM-UC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\Ne4xKUUN3ME2xNU44PDJzIN88US=>	MVXTRW5ITVJ?
SCC-9	NXLDWodlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPFW4hKSzVyPUGxMlgyPTFizszN	NXvYU5ZZW0GQR1XS
HOS	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;3TWM2OD1zMT64Olg{KM7:TR?=	Mny3V2FPT0WU
OE19	NIG3dJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\yZ2lEPTB;MUGuPVM3PyEQvF2=	NEnPZ4dUSU6JRWK=
Mo-T	NVTUVmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFzLkm1OFEh\|ryP	MmnmV2FPT0WU
CAMA-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPhR29KSzVyPUGyMlE3OzNizszN	NV71XZJTW0GQR1XS
U-118-MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vxXWlEPTB;MUKuNlQ1OSEQvF2=	M13HRnNCVkeHUh?=
KS-1	NXjuc5dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF{LkK4N\|Ih\|ryP	NXHXW\|JkW0GQR1XS
JAR	NETPfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3aTm1KSzVyPUGyMlM{PjlizszN	NVH2RpI6W0GQR1XS
ABC-1	NGPlVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nTS2lEPTB;MUKuN\|QyKM7:TR?=	MmnNV2FPT0WU
Daoy	NUHOeYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF{LkS1OFIh\|ryP	NEX3VGtUSU6JRWK=
C3A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlWzTWM2OD1zMj61O\|g2KM7:TR?=	NYnveI1jW0GQR1XS
GT3TKB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfXZXNKSzVyPUGyMlY{OjdizszN	M{jETXNCVkeHUh?=
DMS-273	NX6zfYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2juPGlEPTB;MUKuPFY{OyEQvF2=	MXTTRW5ITVJ?
G-361	NWnVd4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPLfnh7UUN3ME2xNk46OTJ7IN88US=>	NV7HZ2dZW0GQR1XS
RH-18	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPyW25KSzVyPUGzMlI6PjJizszN	M2jaT3NCVkeHUh?=
SN12C	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvrcnlsUUN3ME2xN{4{QDB6IN88US=>	MmXFV2FPT0WU
NCI-H1993	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn2SWZKSzVyPUGzMlQzQDVizszN	M1TnPXNCVkeHUh?=
LOXIMVI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPpTWM2OD1zMz62NVUyKM7:TR?=	MWnTRW5ITVJ?
SK-PN-DW	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfZVYZmUUN3ME2xN{45PDJ5IN88US=>	NGHxZZhUSU6JRWK=
KALS-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NID0fGdKSzVyPUGzMlg2OjVizszN	NELvcGxUSU6JRWK=
LAN-6	NYntT3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TzOmlEPTB;MUSuNlU{KM7:TR?=	MYTTRW5ITVJ?
A549	M3jCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTF2LkS3NVIh\|ryP	NHXXUZFUSU6JRWK=
RD	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGH0VXJKSzVyPUG0MlQ5OTNizszN	MYHTRW5ITVJ?
TGBC1TKB	NYX2blc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF2Lk[2NVUh\|ryP	NVmxPFRqW0GQR1XS
NCI-H630	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFq3fFJKSzVyPUG0Mlk1PjdizszN	NYP0OGJmW0GQR1XS
MIA-PaCa-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTF2Lkm2PUDPxE1?	NFf1c4NUSU6JRWK=
NCI-H1755	NXvZXIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHIWZZKSzVyPUG0Mlk6PTNizszN	M2[2UHNCVkeHUh?=
MOLT-4	M2fXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT6S3FZUUN3ME2xOU4xPDl5IN88US=>	M{\Y[XNCVkeHUh?=
CW-2	NVexR4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTF3LkG0NlEh\|ryP	M3O1cnNCVkeHUh?=
COLO-320-HSR	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHeyOohKSzVyPUG1MlU{ODdizszN	Mlv1V2FPT0WU
UMC-11	NEnqNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fVXWlEPTB;MUWuO\|UzOyEQvF2=	NV\nbZh5W0GQR1XS
MCF7	M1LUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnW5TWM2OD1zNT64NVQ2KM7:TR?=	MlTuV2FPT0WU
NCI-H23	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLjcYZKSzVyPUG1Mlg1OzhizszN	MW\TRW5ITVJ?
HuCCT1	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF3Lki3OEDPxE1?	MYfTRW5ITVJ?
MPP-89	M2T0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLxVoNKSzVyPUG1Mlk1OTdizszN	MVLTRW5ITVJ?
HT55	NVj5VnVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXIRnBKSzVyPUG1Mlk1PzhizszN	MmPZV2FPT0WU
no-11	NYrQRnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Xz[mlEPTB;MUWuPVY3OyEQvF2=	M2PIR3NCVkeHUh?=
GP5d	NUDSPGhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF4LkKxPFch\|ryP	NVr0O3dbW0GQR1XS
BHT-101	NXTQdHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXJTWM2OD1zNj6yOFM6KM7:TR?=	M13KVnNCVkeHUh?=
M059J	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HDVWlEPTB;MU[uNlg1KM7:TR?=	NV\6bnBVW0GQR1XS
D-283MED	M2LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF4LkSyNFkh\|ryP	NFW3fXNUSU6JRWK=
BEN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{H2NWlEPTB;MU[uOVE2PSEQvF2=	Mnu4V2FPT0WU
LB373-MEL-D	NFfkO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPvTWM2OD1zNj63NlMzKM7:TR?=	NGHi[IlUSU6JRWK=
MEL-HO	M4f5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[0[2lEPTB;MU[uPFg2PCEQvF2=	NVSxR5MyW0GQR1XS
GI-ME-N	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1OzcGlEPTB;MU[uPVA{OiEQvF2=	NWrXb4RCW0GQR1XS
RKO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L3b2lEPTB;MUeuNFc1QCEQvF2=	MYPTRW5ITVJ?
MZ2-MEL	M1;MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF5LkGzN{DPxE1?	Mlq1V2FPT0WU
NCI-H1573	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTF5LkK4NlYh\|ryP	NF:3PHRUSU6JRWK=
NCI-H1581	NHfqVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTBXI5KSzVyPUG3MlQ1OTFizszN	MVTTRW5ITVJ?
NCI-H747	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPkfHRKSzVyPUG3MlUzQTdizszN	M1HOV3NCVkeHUh?=
SW1783	NI[3TVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\EN2VKSzVyPUG3MlY1OTVizszN	M13hTnNCVkeHUh?=
Calu-6	NEnlWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fYNmlEPTB;MUeuOlc5OiEQvF2=	NWHFbYhGW0GQR1XS
SF268	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPofZJyUUN3ME2xO{43QTZ7IN88US=>	Mlf4V2FPT0WU
ES8	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoT4TWM2OD1zNz64OVk{KM7:TR?=	M3;Xd3NCVkeHUh?=
KM-H2	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTF5Lkm0NVEh\|ryP	NX7FNJV7W0GQR1XS
D-502MG	M3vYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF5Lkm4NFgh\|ryP	MY\TRW5ITVJ?
HLE	NU[zV4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTF6LkOxOFgh\|ryP	MYPTRW5ITVJ?
SW982	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGj4R4JKSzVyPUG4MlQxPzVizszN	MY\TRW5ITVJ?
MDA-MB-361	M3rRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmS4TWM2OD1zOD61OVg5KM7:TR?=	NXGxZpdnW0GQR1XS
NCI-H1563	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF6LkexNlQh\|ryP	NHLJXFNUSU6JRWK=
MFE-280	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfPTWM2OD1zOD63Nlk{KM7:TR?=	MVjTRW5ITVJ?
U251	NEDhbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TkcWlEPTB;MUiuO\|M1PyEQvF2=	M1HIR3NCVkeHUh?=
KNS-42	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTYTWM2OD1zOD64NFE2KM7:TR?=	NIjofYtUSU6JRWK=
U-266	M4HCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTF6Lki2OFkh\|ryP	M1\3RnNCVkeHUh?=
OVCAR-8	M365cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HkbmlEPTB;MUiuPVI4PiEQvF2=	MY\TRW5ITVJ?
MFH-ino	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnyyTWM2OD1zOD65OlY6KM7:TR?=	M2fYWXNCVkeHUh?=
D-263MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPsS\|FMUUN3ME2xPU4xOTd{IN88US=>	MV7TRW5ITVJ?
NCI-H1437	NHTaUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXq1U3ZmUUN3ME2xPU4xPDZ5IN88US=>	MVrTRW5ITVJ?
NCI-H1048	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\nTWM2OD1zOT6yN\|I3KM7:TR?=	NHHKcYJUSU6JRWK=
NCI-H446	NX3zXWdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrwb21bUUN3ME2xPU4{PTh7IN88US=>	MXPTRW5ITVJ?
NCI-N87	NEe3[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli4TWM2OD1zOT61PVkzKM7:TR?=	NV\PPJB{W0GQR1XS
WM-115	M1TiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NES1fnhKSzVyPUG5MlY4PzRizszN	NYrtT2hWW0GQR1XS
HuH-7	M2nhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jON2lEPTB;MUmuO\|QzOSEQvF2=	MUPTRW5ITVJ?
NCI-H650	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF7Lke1NFgh\|ryP	MkS3V2FPT0WU
TYK-nu	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rKPWlEPTB;MUmuPFM4QCEQvF2=	NV\NN4JTW0GQR1XS
Becker	M3K2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEn0dpNKSzVyPUG5Mlg2PDdizszN	M{KxRXNCVkeHUh?=
BB49-HNC	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLzTWM2OD1zOT65NkDPxE1?	M{Dv[3NCVkeHUh?=
HGC-27	M3v2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ixbmlEPTB;MkCuNVM6PCEQvF2=	NWHXe4Z[W0GQR1XS
SiHa	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLkS45XUUN3ME2yNE4{PzF{IN88US=>	MVnTRW5ITVJ?
LB2518-MEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XOeWlEPTB;MkCuN\|c{QSEQvF2=	MVzTRW5ITVJ?
TE-5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJyLke0PFIh\|ryP	NGrB[HpUSU6JRWK=
IST-SL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rDd2lEPTB;MkCuO\|g4QSEQvF2=	NYiycJdIW0GQR1XS
A375	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTJzLkC1Olch\|ryP	NH7yOplUSU6JRWK=
MC116	NIK4ZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJzLkC3NlMh\|ryP	NYezdVNNW0GQR1XS
GI-1	M{fSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJzLkG3JO69VQ>?	MmHYV2FPT0WU
HOP-62	M3G0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvPVHlKSzVyPUKxMlI4QDRizszN	NFjEW3VUSU6JRWK=
PA-1	M3fVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJzLkK3PFch\|ryP	MXrTRW5ITVJ?
HT	M3;Hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJzLkSzN\|Eh\|ryP	NYTpdWhoW0GQR1XS
HUTU-80	NXLjeFFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DGfWlEPTB;MkGuOFM{PiEQvF2=	MY\TRW5ITVJ?
NCI-H1975	NHzT[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL2TWM2OD1{MT60OlEh\|ryP	MX7TRW5ITVJ?
GAK	M{H0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVT2SmhoUUN3ME2yNU41QTlizszN	NFza[ZRUSU6JRWK=
SK-N-AS	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfV[pBKSzVyPUKxMlU3OTlizszN	NFHVfJFUSU6JRWK=
OE33	NUjodJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnqzTWM2OD1{MT62NFQ3KM7:TR?=	MXHTRW5ITVJ?
YKG-1	NUnRc3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPaWJpKSzVyPUKxMlY2PDVizszN	MWPTRW5ITVJ?
CAL-85	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfRTWM2OD1{MT65N\|A2KM7:TR?=	MX3TRW5ITVJ?
NCI-H2347	NXK3RWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWH6[mh3UUN3ME2yNU46PDJ6IN88US=>	MVvTRW5ITVJ?
PANC-08-13	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fOUGlEPTB;MkKuNFEyQSEQvF2=	MmfHV2FPT0WU
SK-N-FI	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHqWZU6UUN3ME2yNk4{ODd2IN88US=>	NH70RoZUSU6JRWK=
NEC8	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ{LkWwO\|gh\|ryP	NXT3Sm5KW0GQR1XS
AN3-CA	M{S4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4juU2lEPTB;MkKuOlA5PCEQvF2=	NFjrb4tUSU6JRWK=
HuO9	NGmzRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXVTWM2OD1{Mj63N\|k3KM7:TR?=	MkLrV2FPT0WU
COLO-800	M{P1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFz5SVhKSzVyPUKyMlc3PTNizszN	M2fJenNCVkeHUh?=
HT-29	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ{Lki4NlMh\|ryP	NXHPOms2W0GQR1XS
OC-314	M1TOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFj0[3lKSzVyPUKyMlg5PDVizszN	NYnLSG1jW0GQR1XS
G-401	NWjV[3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{njWWlEPTB;MkOuNFQ3OiEQvF2=	M2HWXXNCVkeHUh?=
Saos-2	M4LoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3YUZU4UUN3ME2yN{42OTh{IN88US=>	NUPWdlQzW0GQR1XS
UACC-62	M1jwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HPdWlEPTB;MkOuOVg{OyEQvF2=	M1H6SXNCVkeHUh?=
D-247MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4q1SmlEPTB;MkOuO\|k{QSEQvF2=	NYO3OFlQW0GQR1XS
COLO-741	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJ\|Lkm1OlUh\|ryP	MXnTRW5ITVJ?
ES3	NGTRO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJ2LkCwNlMh\|ryP	Ml3aV2FPT0WU
LNCaP-Clone-FGC	M4PITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFL4U4RKSzVyPUK0MlAzOTFizszN	MkP5V2FPT0WU
SW1710	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPuZ5BXUUN3ME2yOE4yPTB4IN88US=>	NE\IT4xUSU6JRWK=
LU-99A	NXXBTY97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrJUWVZUUN3ME2yOE4yQDRzIN88US=>	NEX0bnNUSU6JRWK=
HOP-92	M2WyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTaWFhoUUN3ME2yOE44OjVizszN	NEXIXGdUSU6JRWK=
LS-123	NVrVfpN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Lw[mlEPTB;MkSuPVYyPCEQvF2=	NXzHTYpKW0GQR1XS
T84	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\PPXAzUUN3ME2yOE46PzZ3IN88US=>	MUfTRW5ITVJ?
HCT-116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPXR2xKSzVyPUK1MlQyQDZizszN	M3znbnNCVkeHUh?=
M14	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DJ[GlEPTB;MkWuOFQ1PyEQvF2=	NUfke5hrW0GQR1XS
OCUB-M	NWWxN4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\QTWM2OD1{NT60OFU3KM7:TR?=	M4HHXXNCVkeHUh?=
MKN45	NXHx[oZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;SSm05UUN3ME2yOU43OzF3IN88US=>	M4XzfnNCVkeHUh?=
LCLC-97TM1	NHLVW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnXVHVTUUN3ME2yOU44Ojh3IN88US=>	NHy2bFFUSU6JRWK=
RVH-421	M1XvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\wbWlEPTB;MkWuPFE3OSEQvF2=	MWDTRW5ITVJ?
NKS-81-FD	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJ3LkmwNlEh\|ryP	Mle4V2FPT0WU
NCI-H596	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmCwTWM2OD1{Nj6wOFg4KM7:TR?=	NGnxOHZUSU6JRWK=
GB-1	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHTTWM2OD1{Nj6xPFc6KM7:TR?=	MlnoV2FPT0WU
ZR-75-30	NHPBfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJ4LkKyPVch\|ryP	NFW1fGFUSU6JRWK=
U-2-OS	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJ4LkO3OVch\|ryP	MW\TRW5ITVJ?
HuP-T3	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[zTWM2OD1{Nj62NVAzKM7:TR?=	NXj0VW01W0GQR1XS
MOLT-16	NELsZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHnWnBXUUN3ME2yOk43OTZ4IN88US=>	M2PFS3NCVkeHUh?=
U-87-MG	M1[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ4Lke0N\|gh\|ryP	NHjy[5pUSU6JRWK=
8505C	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17ZSmlEPTB;Mk[uPVEzPiEQvF2=	Ml;GV2FPT0WU
SK-MEL-3	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIG4cXBKSzVyPUK2Mlk5OjhizszN	NVXsd3RqW0GQR1XS
COLO-824	NGLKepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHDTWM2OD1{Nz6yNVk2KM7:TR?=	MWHTRW5ITVJ?
EW-1	NHrZSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJ5LkO1OVQh\|ryP	NUTuc4JZW0GQR1XS
UACC-257	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkS2TWM2OD1{Nz6zPFA1KM7:TR?=	NEHpSIpUSU6JRWK=
Hs-578-T	M1y3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTJ5LkWyPVkh\|ryP	M3vse3NCVkeHUh?=
UACC-893	M33D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;6O49KSzVyPUK3MlY3OzFizszN	NVq5cJh5W0GQR1XS
MHH-NB-11	M4TwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH3d286UUN3ME2yO{45ODB5IN88US=>	NI\EO\|hUSU6JRWK=
KYSE-410	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJ6LkK3O\|kh\|ryP	M1\odXNCVkeHUh?=
SF126	NFywS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmL0TWM2OD1{OD63OFM2KM7:TR?=	M2TBXHNCVkeHUh?=
HT-144	NGW2[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFSze2RKSzVyPUK5MlM{PjJizszN	M4LOeXNCVkeHUh?=
SW1573	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fQUmlEPTB;MkmuN\|UxQSEQvF2=	NFXk[2pUSU6JRWK=
SW620	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LET2lEPTB;MkmuN\|Y1OSEQvF2=	NG\EVmtUSU6JRWK=
SCH	NHTlSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJ7Lki4N\|Eh\|ryP	NF7wS2RUSU6JRWK=
EW-22	NEXLPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNyLkG5Olkh\|ryP	NFvzNm5USU6JRWK=
H4	NWTDZ495T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTpTWM2OD1\|MD60OlU1KM7:TR?=	M3PmS3NCVkeHUh?=
CAS-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnaTWM2OD1\|MD63PFU6KM7:TR?=	M3fYWHNCVkeHUh?=
MG-63	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fTbWlEPTB;M{CuPFQ4QCEQvF2=	NEDSR4NUSU6JRWK=
MDA-MB-415	NY\OR4Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnlUpNKSzVyPUOxMlE4PTNizszN	M3zF[XNCVkeHUh?=
NCI-H1395	NEe5V2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHv6VmVKSzVyPUOxMlI{OjhizszN	M{WycHNCVkeHUh?=
Ca-Ski	M17Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTNzLkOxO\|ch\|ryP	NV3wWmtJW0GQR1XS
BxPC-3	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTNzLkO3Nlkh\|ryP	M2DndXNCVkeHUh?=
A3-KAW	M1[2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXvR5hnUUN3ME2zNU41PDdzIN88US=>	MnXxV2FPT0WU
T-24	M2XHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3S0eGlEPTB;M{GuO\|M3OiEQvF2=	MU\TRW5ITVJ?
NCI-H2029	NIDFfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTNzLke3OlUh\|ryP	M1LZZ3NCVkeHUh?=
YAPC	M4G1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLWUmhKSzVyPUOyMlA1ODdizszN	NImwXmJUSU6JRWK=
SK-MEL-2	NEmwSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTN{LkC1NkDPxE1?	MkPjV2FPT0WU
LS-513	MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjiTWM2OD1\|Mj6xNVg4KM7:TR?=	MknMV2FPT0WU
AsPC-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTVTWM2OD1\|Mj6zOlA2KM7:TR?=	M2P6XHNCVkeHUh?=
KYSE-150	NG\kO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7EWnN6UUN3ME2zNk4{Pzd\|IN88US=>	NHyzXnpUSU6JRWK=
NCI-H520	M2XYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTN{LkS0PFIh\|ryP	MnjoV2FPT0WU
JEG-3	M4PNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTN\|LkC5O\|Eh\|ryP	MlG4V2FPT0WU
GMS-10	M1jKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfQSZJKSzVyPUOzMlMxODRizszN	MV3TRW5ITVJ?
HT-1080	M4i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTpXI9rUUN3ME2zN{4{QSEQvF2=	M4jvVnNCVkeHUh?=
NCI-H1651	NETiOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q5VWlEPTB;M{OuN\|k3KM7:TR?=	M1q0cHNCVkeHUh?=
NCI-H2122	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHuRYFTUUN3ME2zN{42PTd2IN88US=>	MWTTRW5ITVJ?
ES5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO2Um82UUN3ME2zN{44Ojl{IN88US=>	M4XueXNCVkeHUh?=
8305C	M1fVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEOwZVhKSzVyPUOzMlk6OzdizszN	NX[1XJgyW0GQR1XS
KM12	NWfhfYlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHFSldqUUN3ME2zOE4xPDd6IN88US=>	MUPTRW5ITVJ?
HCT-15	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfyTWM2OD1\|ND6xNlch\|ryP	MUfTRW5ITVJ?
OVCAR-5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXflNnVkUUN3ME2zOE4zOTh{IN88US=>	M37wR3NCVkeHUh?=
NCI-H2291	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIe3XZZKSzVyPUO0MlI1PzJizszN	NVvtfZB{W0GQR1XS
CP50-MEL-B	NEPGeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnTZ4xUUUN3ME2zOE43PTl{IN88US=>	M2HvSHNCVkeHUh?=
C-33-A	NEDVR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzpS3NqUUN3ME2zOE43QDV5IN88US=>	NGXtcohUSU6JRWK=
NCI-H2452	NIrxb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfG[WtKUUN3ME2zOE44QDh{IN88US=>	MmfoV2FPT0WU
MDA-MB-157	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkP6TWM2OD1\|ND64NVk{KM7:TR?=	MX\TRW5ITVJ?
LN-405	M1TaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTN3LkSzNFgh\|ryP	M1ezNnNCVkeHUh?=
MDA-MB-231	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnm5TWM2OD1\|NT61NFU1KM7:TR?=	NELueYZUSU6JRWK=
EW-24	NEmxTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTN3Lk[zN\|Uh\|ryP	MoLEV2FPT0WU
MKN28	NEPQZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnKTWM2OD1\|NT64NlM3KM7:TR?=	NW\OdXRjW0GQR1XS
KINGS-1	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\IXY9KSzVyPUO1Mlg1OzRizszN	M{KxRnNCVkeHUh?=
LC-2-ad	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XhSWlEPTB;M{[uOlk6KM7:TR?=	M1vNVXNCVkeHUh?=
IGR-1	M4PCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[xTWM2OD1\|Nj63NFc2KM7:TR?=	M1y2[3NCVkeHUh?=
SW626	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\FTWM2OD1\|Nz6wOFE4KM7:TR?=	MW\TRW5ITVJ?
ONS-76	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P4V2lEPTB;M{euNVMxQSEQvF2=	NXfoSXg4W0GQR1XS
T98G	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDUZ5VkUUN3ME2zO{45PjN3IN88US=>	M{DzenNCVkeHUh?=
NB14	M17pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjqTWM2OD1\|OD60OVQ1KM7:TR?=	M4TPS3NCVkeHUh?=
D-423MG	NFOyUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7TTWM2OD1\|OD60PFY6KM7:TR?=	NXToeJRQW0GQR1XS
NCI-H510A	NV7I[ZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN6Lk[0OVEh\|ryP	MULTRW5ITVJ?
NMC-G1	NYLhWpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr1N2pKSzVyPUO4MlczOjJizszN	MWHTRW5ITVJ?
SW948	MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTN6Lki5OFkh\|ryP	MUTTRW5ITVJ?
MFM-223	NWXyPIR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXU[4JKSzVyPUO4Mlk1OzFizszN	MmqyV2FPT0WU
PAN1	M2Pv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rWW2lEPTB;M{iuPVkyQSEQvF2=	M2LkdnNCVkeHUh?=
MZ7-mel	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN7LkGxPVkh\|ryP	M3;lNnNCVkeHUh?=
COLO-679	NX3GZ3RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\XbXlKSzVyPUO5Mlk4ODhizszN	NUG4PZJwW0GQR1XS
SW872	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjOdWlqUUN3ME20NE4zODNzIN88US=>	MVfTRW5ITVJ?
HT-1197	NYW2WYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTRyLkK4Olkh\|ryP	MXjTRW5ITVJ?
ES6	NEnzO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTRyLkS1OVIh\|ryP	MVzTRW5ITVJ?
SNU-387	M2H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTRyLkiyN\|gh\|ryP	MkXzV2FPT0WU
T47D	M1u4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTuTWM2OD12MT6wNVkzKM7:TR?=	Mkj3V2FPT0WU
G-402	NIKxXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rTdmlEPTB;NEGuNFgxQSEQvF2=	MWfTRW5ITVJ?
MZ1-PC	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTRzLkixJO69VQ>?	NWrKO\|BYW0GQR1XS
SW1417	M3\aXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfHWpJ4UUN3ME20Nk4{ODNizszN	M1rGZXNCVkeHUh?=
RERF-LC-MS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIr3VW9KSzVyPUSyMlUxQDdizszN	M{Th[XNCVkeHUh?=
SF539	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3lbohKSzVyPUSyMlU2OjlizszN	NWLteJdsW0GQR1XS
ESS-1	NXP3cphvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVW2O5RJUUN3ME20N{42PTV6IN88US=>	MVjTRW5ITVJ?
RO82-W-1	M1W5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTR\|Lk[xOVMh\|ryP	M3q0TnNCVkeHUh?=
S-117	M1TkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHhTWM2OD12Mz62PVU5KM7:TR?=	NWTMNYFrW0GQR1XS
SW756	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XHTmlEPTB;NEOuPFI1OiEQvF2=	NIH2e4tUSU6JRWK=
CP66-MEL	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT3TWM2OD12NT63NVQ{KM7:TR?=	MUnTRW5ITVJ?
H-EMC-SS	NXrzUYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTR3Lke2PVMh\|ryP	M4nYc3NCVkeHUh?=
NCI-H2052	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLVTWM2OD12NT65NFI4KM7:TR?=	M4HDN3NCVkeHUh?=
SW684	NG\oN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTR5LkCwPFEh\|ryP	MYnTRW5ITVJ?
HCC1569	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXvTWM2OD12Nz6xOlU5KM7:TR?=	NXnTd\|kyW0GQR1XS
KGN	NU\uR\|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnBS21KSzVyPUS3MlM{OTFizszN	NUfycHJjW0GQR1XS
LCLC-103H	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTR5LkS0NFQh\|ryP	M1TpUHNCVkeHUh?=
SW780	NHTOUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITmWo5KSzVyPUS3MlY{PTFizszN	NID3d2hUSU6JRWK=
NCI-H1703	NGnCOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTR6LkOzOVIh\|ryP	NVXROpNrW0GQR1XS
HCC1395	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7GZZlSUUN3ME20PE44PDN{IN88US=>	MYfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: NR6, NR6M and NR6W cells Concentrations: 0-2 μM Incubation Time: 72 hours Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay. (Only for Reference)
Animal Research:^[3]	+ Expand Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells. Formulation: 0.5% polysorbate Dosages: 100 mg/kg Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

+ Expand

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products4

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 165 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 165 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)